Gormley Glenn 4

What Happened
Glenn Gormley, a director of Aktis Oncology, was granted stock options covering 37,866 shares on April 15, 2026. The Form 4 reports the acquisition as an award/derivative at $0.00 per share (transaction code A); no cash price or immediate sale was reported.

Key Details

• Transaction date: 2026-04-15; Form 4 filed 2026-04-16 (timely filing).
• Transaction type: Grant of stock options (derivative securities), code A.
• Quantity and price: 37,866 option shares @ $0.00 (reported acquisition value $0).
• Vesting (Footnote F1): 1/3 vests on April 15, 2027, then 1/3 annually thereafter, subject to continuous service.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing status: Timely (filed the day after the transaction).

Context
This was a compensation grant of options, not an open-market purchase or sale. The options only translate into owned shares if and when they vest (and are exercised); they do not by themselves indicate an immediate market buy or sell. Grants like this are common for director compensation and are primarily a retention/incentive tool rather than a direct signal of trading intent.